All In Biotech

Free tool

FAERS Monitor: Pre-Pen

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming BLA 050114 or its brand name (Pre-Pen, Benzylpenicilloyl Polylysine). Reports on generic versions are filed under their own applications.

Reports

35

Serious

11

31% of reports

Hospitalization

1

Death reported

0

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • pruritus12
  • false negative investigation result9
  • urticaria6
  • anaphylactic reaction4
  • skin test positive4
  • erythema3
  • feeling hot3
  • maternal exposure during pregnancy3
  • throat tightness3
  • drug hypersensitivity2
  • dyspnoea2
  • exposure during pregnancy2
  • peripheral swelling2
  • rash2
  • skin test negative2

Reports by year received

View as table
YearReports
20152
20161
20185
20196
20207
20215
20221
20232
20244
20251
20261

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,124 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
skin test negative212152.53118.813,398
false negative investigation resultSignal97801.04420.561,808
skin test positiveSignal42590.11027.57,891
throat tightnessSignal366.722.6134
anaphylactic reactionSignal443.517.3127
feeling hotSignal329.410.057
urticariaSignal621.510.499
maternal exposure during pregnancySignal320.26.937
exposure during pregnancy219.35.019
pruritusSignal1218.811.9188
erythemaSignal38.83.014
peripheral swelling27.82.06
drug hypersensitivity26.21.64
rash22.80.71
dyspnoea22.10.60

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.